^
Association details:
| Biomarker: | RET C618R |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Excerpt:
RECIST Response and Correlative Studies....As shown in Table 3 and Figure 3, 17 patients had a decrease in either the calcitonin or CEA level, and 11 patients had a decrease in both tumor markers….However, neither the timing nor the degree of tumor marker response significantly correlated with the degree or duration of RECIST response.
DOI:
10.1200/JCO.2009.25.0068
Trial ID:
